Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Allogene Therapeutics Inc (NASDAQ: ALLO) was $1.11 for the day, up 1.83% from the previous closing price of $1.09. In other words, the price has increased by $1.83 from its previous closing price. On the day, 3.17 million shares were traded.
Ratios:
Our analysis of ALLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.71 and its Current Ratio is at 9.71. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.21.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 21 ’25 when Yoshiyama Annie sold 9,601 shares for $1.41 per share. The transaction valued at 13,537 led to the insider holds 130,663 shares of the business.
Yoshiyama Annie bought 9,601 shares of ALLO for $13,537 on Apr 21 ’25. On Mar 14 ’25, another insider, Chang David D, who serves as the President and CEO of the company, sold 46,668 shares for $1.96 each. As a result, the insider received 91,469 and left with 5,276,569 shares of the company.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -27.23%, while the 200-Day Moving Average is calculated to be -48.39%.
Shares Statistics:
A total of 218.60M shares are outstanding, with a floating share count of 149.47M. Insiders hold about 34.30% of the company’s shares, while institutions hold 66.09% stake in the company.
